1
|
Fernández A, Herrera D, Hoare A, Hernández M, Torres VA. Lipopolysaccharides from Porphyromonas endodontalis and Porphyromonas gingivalis promote angiogenesis via Toll-like-receptors 2 and 4 pathways in vitro. Int Endod J 2023; 56:1270-1283. [PMID: 37461231 DOI: 10.1111/iej.13957] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 07/11/2023] [Accepted: 07/12/2023] [Indexed: 08/08/2023]
Abstract
AIM Angiogenesis contributes to the development of apical periodontitis, periodontitis, and other oral pathologies; however, it remains unclear how this process is triggered. The aim was to evaluate whether lipopolysaccharide (LPS) from Porphyromonas endodontalis and Porphyromonas gingivalis induced angiogenesis-related effects in vitro via TLR2 and TLR4. METHODOLOGY Porphyromonas endodontalis LPS (ATCC 35406 and clinical isolate) was purified with TRIzol, whereas P. gingivalis LPS was obtained commercially. The effects of the different LPS (24 h) in endothelial cell migration were analysed by Transwell assays, following quantification in an optical microscope (40×). The effects of LPS on FAK Y397 phosphorylation were assessed by Western blotting. Angiogenesis in vitro was determined in an endothelial tube formation assay (14 h) in Matrigel in the absence or presence of either LPS. IL-6 and VEGF-A levels were determined in cell supernatants, following 24 h treatment with LPS, and measured in multiplex bead immunoassay. The involvement of TLR2 and TLR4 was assessed with blocking antibodies. The statistical analysis was performed using STATA 12® (StataCorp LP). RESULTS The results revealed that P. endodontalis LPS, but not P. gingivalis LPS, stimulated endothelial cell migration. Pre-treatment with anti-TLR2 and anti-TLR4 antibodies prevented P. endodontalis LPS-induced cell migration. P. endodontalis LPS promoted FAK phosphorylation on Y397, as observed by an increased p-FAK/FAK ratio. Both P. gingivalis and P. endodontalis LPS (ATCC 35406) induced endothelial tube formation in a TLR-2 and -4-dependent manner, as shown by using blocking antibodies, however, only TLR2 blocking decreased tube formation induced by P. endodontalis (clinical isolate). Moreover, all LPS induced IL-6 and VEGF-A synthesis in endothelial cells. TLR2 and TLR4 were required for IL-6 induction by P. endodontalis LPS (ATCC 35406), while only TLR4 was involved in IL-6 secretion by the other LPS. Finally, VEGF-A synthesis did not require TLR signalling. CONCLUSION Porphyromonas endodontalis and P. gingivalis LPS induced angiogenesis via TLR2 and TLR4. Collectively, these data contribute to understanding the role of LPS from Porphyromonas spp. in angiogenesis and TLR involvement.
Collapse
Affiliation(s)
- Alejandra Fernández
- Laboratory of Periodontal Biology, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
- Faculty of Dentistry, Universidad Andres Bello, Santiago, Chile
| | - Daniela Herrera
- Faculty of Dentistry, Institute for Research in Dental Sciences, Universidad de Chile, Santiago, Chile
| | - Anilei Hoare
- Department of Pathology and Oral Medicine, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
- Laboratory of Oral Microbiology and Immunology, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
| | - Marcela Hernández
- Laboratory of Periodontal Biology, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
- Department of Pathology and Oral Medicine, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
| | - Vicente A Torres
- Faculty of Dentistry, Institute for Research in Dental Sciences, Universidad de Chile, Santiago, Chile
- Millennium Institute on Immunology and Immunotherapy, Universidad de Chile, Santiago, Chile
- Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile, Santiago, Chile
| |
Collapse
|
2
|
Abstract
BACKGROUND Atherosclerotic occlusions decrease blood flow to the lower limbs, causing ischemia and tissue loss in patients with peripheral artery disease (PAD). No effective medical therapies are currently available to induce angiogenesis and promote perfusion recovery in patients with severe PAD. Clinical trials aimed at inducing vascular endothelial growth factor (VEGF)-A levels, a potent proangiogenic growth factor to induce angiogenesis, and perfusion recovery were not successful. Alternate splicing in the exon-8 of VEGF-A results in the formation of VEGFxxxa (VEGF165a) and VEGFxxxb (VEGF165b) isoforms with existing literature focusing on VEGF165b's role in inhibiting vascular endothelial growth factor receptor 2-dependent angiogenesis. However, we have recently shown that VEGF165b blocks VEGF-A-induced endothelial vascular endothelial growth factor receptor 1 (VEGFR1) activation in ischemic muscle to impair perfusion recovery. Because macrophage-secreted VEGF165b has been shown to decrease angiogenesis in peripheral artery disease, and macrophages were well known to play important roles in regulating ischemic muscle vascular remodeling, we examined the role of VEGF165b in regulating macrophage function in PAD. METHODS Femoral artery ligation and resection were used as an in vivo preclinical PAD model, and hypoxia serum starvation was used as an in vitro model for PAD. Experiments including laser-Doppler perfusion imaging, adoptive cell transfer to ischemic muscle, immunoblot analysis, ELISAs, immunostainings, flow cytometry, quantitative polymerase chain reaction analysis, and RNA sequencing were performed to determine a role of VEGF165b in regulating macrophage phenotype and function in PAD. RESULTS First, we found increased VEGF165b expression with increased M1-like macrophages in PAD versus non-PAD (controls) muscle biopsies. Next, using in vitro hypoxia serum starvation, in vivo pre clinical PAD models, and adoptive transfer of VEGF165b-expressing bone marrow-derived macrophages or VEGFR1+/- bone marrow-derived macrophages (M1-like phenotype), we demonstrate that VEGF165b inhibits VEGFR1 activation to induce an M1-like phenotype that impairs ischemic muscle neovascularization. Subsequently, we found S100A8/S100A9 as VEGFR1 downstream regulators of macrophage polarization by RNA-Seq analysis of hypoxia serum starvation-VEGFR1+/+ versus hypoxia serum starvation-VEGFR1+/- bone marrow-derived macrophages. CONCLUSIONS In our current study, we demonstrate that increased VEGF165b expression in macrophages induces an antiangiogenic M1-like phenotype that directly impairs angiogenesis. VEGFR1 inhibition by VEGF165b results in S100A8/S100A9-mediated calcium influx to induce an M1-like phenotype that impairs ischemic muscle revascularization and perfusion recovery.
Collapse
Affiliation(s)
- Vijay Chaitanya Ganta
- Robert M. Berne Cardiovascular Research Center (V.C.G., M.C., B.H.A.), University of Virginia, Charlottesville.,Division Cardiovascular Medicine, Department of Medicine (V.C.G., B.H.A.), University of Virginia, Charlottesville
| | - Min Choi
- Robert M. Berne Cardiovascular Research Center (V.C.G., M.C., B.H.A.), University of Virginia, Charlottesville
| | - Charles R Farber
- Department of Public Health Sciences (C.R.F.), University of Virginia, Charlottesville
| | - Brian H Annex
- Robert M. Berne Cardiovascular Research Center (V.C.G., M.C., B.H.A.), University of Virginia, Charlottesville.,Division Cardiovascular Medicine, Department of Medicine (V.C.G., B.H.A.), University of Virginia, Charlottesville
| |
Collapse
|
3
|
Zhong J, Li J, Wei J, Huang D, Huo L, Zhao C, Lin Y, Chen W, Wei Y. Plumbagin Restrains Hepatocellular Carcinoma Angiogenesis by Stromal Cell-Derived Factor (SDF-1)/CXCR4-CXCR7 Axis. Med Sci Monit 2019; 25:6110-6119. [PMID: 31415486 PMCID: PMC6707097 DOI: 10.12659/msm.915782] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 04/25/2019] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Anti-angiogenic therapy has recently emerged as a highly promising therapeutic strategy for treating hepatocellular carcinoma (HCC). MATERIAL AND METHODS We assessed cellular proliferation, invasion, and activation of growth factors (VEGF and IL-8) with SDF-1 induced in the hepatocellular carcinoma cell line SMMC-7721, and this progression was limited by plumbagin (PL). The human umbilical vein endothelial cell line HUVEC was co-cultured with SDF-1-induced SMMC-7721, and the expressions of CXCR7, CXCR4, and PI3K/Akt pathways after PL treatment were detected by RT-PCR and Western blot analysis. RESULTS The treatment of the hepatoma cell line SMMC-7721 with SDF-1 resulted in enhanced secretion of the angiogenic factors, IL-8 and VEGF, and shows that these stimulatory effects are abolished by PL. The study further demonstrated that PL not only abolishes SDF-1-induced formation of endothelial tubes, but also inhibits expression of CXCR4 and CXCR7, and partially prevents activation of angiogenic signaling pathways. CONCLUSIONS The effect of PL on the SDF-1-CXCR4/CXCR7 axis has become an attractive target for inhibiting angiogenesis in hepatoma cells. Our results provide more evidence for the clinical application of PL as part of traditional Chinese medicine in modern cancer treatment.
Collapse
Affiliation(s)
- Jing Zhong
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Junxuan Li
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Jiexiao Wei
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Delun Huang
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Lini Huo
- Department of Organic Chemistry, Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Chuan Zhao
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Yuning Lin
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Wanjun Chen
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| | - Yanfei Wei
- Department of Physiology, Faculty of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China
| |
Collapse
|
4
|
Abstract
Craniofacial bones, separate from the appendicular skeleton, bear a significant amount of strain and stress generated from mastication-related muscles. Current research on the regeneration of craniofacial bone focuses on the reestablishment of an elaborate vascular network. In this review, current challenges and efforts particularly in advances of scaffold properties and techniques for vascularization remodeling in craniofacial bone tissue engineering will be discussed. A microenvironment of ischemia and hypoxia in the biomaterial core drives propagation and reorganization of endothelial progenitor cells (EPCs) to assemble into a primitive microvascular framework. Co-culture strategies and delivery of vasculogenic molecules enhance EPCs' differentiation and stimulate the host regenerative response to promote vessel sprouting and strength. To optimize structural and vascular integration, well-designed microstructures of scaffolds are biologically considered. Proper porous structures, matrix stiffness, and surface morphology of scaffolds have a profound influence on cell behaviors and thus affect revascularization. In addition, advanced techniques facilitating angiogenesis and vaculogenesis have also been discussed. Oxygen delivery biomaterials, scaffold-free cell sheet techniques, and arteriovenous loop-induced axial vascularization strategies bring us new understanding and powerful strategies to manage revascularization of large craniofacial bone defects. Although promising histological results have been achieved, the efficient perfusion and functionalization of newly formed vessels are still challenging.
Collapse
Affiliation(s)
- T Tian
- 1 State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - T Zhang
- 1 State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Y Lin
- 1 State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - X Cai
- 1 State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| |
Collapse
|
5
|
Abstract
Low efficiency of deriving endothelial cells (ECs) from adult stem cells hampers their utilization in tissue engineering studies. The purpose of this study was to investigate whether suppression of transforming growth factor beta (TGF-β) signaling could enhance the differentiation efficiency of dental pulp-derived stem cells into ECs. We initially used vascular endothelial growth factor A (VEGF-A) to stimulate 2 dental pulp-derived stem cells (dental pulp stem cells and stem cells from human exfoliated deciduous teeth [SHED]) and compared their differentiation capacity into ECs. We further evaluated whether the vascular endothelial growth factor receptor I (VEGF-RI)-specific ligand placental growth factor-1 (PlGF-1) could mediate endothelial differentiation. Finally, we investigated whether the TGF-β signaling inhibitor SB-431542 could enhance the inductive effect of VEGF-A on endothelial differentiation, as well as the underlying mechanisms involved. ECs differentiated from dental pulp-derived stem cells exhibited the typical phenotypes of primary ECs, with SHED possessing a higher endothelial differentiation potential than dental pulp stem cells. VEGFR1-specific ligand-PLGF exerted a negligible effect on SHED-ECs differentiation. Compared with VEGF-A alone, the combination of VEGF-A and SB-431542 significantly enhanced the endothelial differentiation of SHED. The presence of SB-431542 inhibited the phosphorylation of Suppressor of Mothers Against Decapentaplegic 2/3 (SMAD2/3), allowing for VEGF-A-dependent phosphorylation and upregulation of VEGFR2. Our results indicate that the combination of VEGF-A and SB-431542 could enhance the differentiation of dental pulp-derived stem cells into endothelial cells, and this process is mediated through enhancement of VEGF-A-VEGFR2 signaling and concomitant inhibition of TGF-β-SMAD2/3 signaling.
Collapse
Affiliation(s)
- J G Xu
- 1 Endodontology, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China
| | - T Gong
- 1 Endodontology, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.,2 HKU Shenzhen Institute of Research and Innovation, Hong Kong, China
| | - Y Y Wang
- 3 Key Laboratory of Oral Diseases Research of Anhui Province, Hefei, China
| | - T Zou
- 1 Endodontology, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.,2 HKU Shenzhen Institute of Research and Innovation, Hong Kong, China
| | - B C Heng
- 1 Endodontology, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.,2 HKU Shenzhen Institute of Research and Innovation, Hong Kong, China
| | - Y Q Yang
- 4 Orthodontics, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China
| | - C F Zhang
- 1 Endodontology, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.,2 HKU Shenzhen Institute of Research and Innovation, Hong Kong, China
| |
Collapse
|
6
|
Grandhi RK, Lee S, Abd-Elsayed A. The Relationship Between Regional Anesthesia and Cancer: A Metaanalysis. Ochsner J 2017; 17:345-361. [PMID: 29230120 PMCID: PMC5718448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023] Open
Abstract
BACKGROUND Some studies have suggested using epidural analgesia after cancer surgery to reduce metastasis. This article examines the relationship between regional anesthesia (RA) and cancer metastasis in an array of cancers. METHODS We conducted a review of the literature using PubMed and included 67,577 patients across 28 studies in a metaanalysis, evaluating the hazard ratios (HRs) of overall survival, recurrence-free survival, and biochemical recurrence-free survival. RESULTS We found no benefit to RA as it relates to cancer. The HR was 0.92 for overall survival, 1.06 for recurrence-free survival, and 1.05 for biochemical recurrence-free survival. Despite the overall analysis showing no benefit, we found some benefit when we evaluated only the randomized trials. However, we found no significant benefit of RA when we evaluated the cancers (gastrointestinal, prostate, breast, and ovarian) individually. CONCLUSION This metaanalysis shows that RA has no overall survival, recurrence-free survival, or biochemical recurrence-free survival benefit. However, some individual studies have shown significant benefit in terms of cancer recurrence. Further, RA reduces the use of opioids, which has led to some secondary benefits. Further studies are needed to establish the benefits of RA as it relates to cancer.
Collapse
Affiliation(s)
- Ravi K. Grandhi
- Department of Anesthesiology, Maimonides Medical Center, Brooklyn, NY
| | - Samuel Lee
- Department of Anesthesiology, University of Cincinnati, Cincinnati, OH
| | - Alaa Abd-Elsayed
- Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI
| |
Collapse
|
7
|
Patel J, Seppanen EJ, Rodero MP, Wong HY, Donovan P, Neufeld Z, Fisk NM, Francois M, Khosrotehrani K. Functional Definition of Progenitors Versus Mature Endothelial Cells Reveals Key SoxF-Dependent Differentiation Process. Circulation 2016; 135:786-805. [PMID: 27899395 DOI: 10.1161/circulationaha.116.024754] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2016] [Accepted: 11/16/2016] [Indexed: 12/13/2022]
Abstract
BACKGROUND During adult life, blood vessel formation is thought to occur via angiogenic processes involving branching from existing vessels. An alternate proposal suggests that neovessels form from endothelial progenitors able to assemble the intimal layers. We here aimed to define vessel-resident endothelial progenitors in vivo in a variety of tissues in physiological and pathological situations such as normal aorta, lungs, and wound healing, tumors, and placenta, as well. METHODS Based on protein expression levels of common endothelial markers using flow cytometry, 3 subpopulations of endothelial cells could be identified among VE-Cadherin+ and CD45- cells. RESULTS Lineage tracing by using Cdh5creERt2/Rosa-YFP reporter strategy demonstrated that the CD31-/loVEGFR2lo/intracellular endothelial population was indeed an endovascular progenitor (EVP) of an intermediate CD31intVEGFR2lo/intracellular transit amplifying (TA) and a definitive differentiated (D) CD31hiVEGFR2hi/extracellular population. EVP cells arose from vascular-resident beds that could not be transferred by bone marrow transplantation. Furthermore, EVP displayed progenitor-like status with a high proportion of cells in a quiescent cell cycle phase as assessed in wounds, tumors, and aorta. Only EVP cells and not TA and D cells had self-renewal capacity as demonstrated by colony-forming capacity in limiting dilution and by transplantation in Matrigel plugs in recipient mice. RNA sequencing revealed prominent gene expression differences between EVP and D cells. In particular, EVP cells highly expressed genes related to progenitor function including Sox9, Il33, Egfr, and Pdfgrα. Conversely, D cells highly expressed genes related to differentiated endothelium including Ets1&2, Gata2, Cd31, Vwf, and Notch. The RNA sequencing also pointed to an essential role of the Sox18 transcription factor. The role of SOX18 in the differentiation process was validated by using lineage-tracing experiments based on Sox18CreERt2/Rosa-YFP mice. Besides, in the absence of functional SOX18/SOXF, EVP progenitors were still present, but TA and D populations were significantly reduced. CONCLUSIONS Our findings support an entirely novel endothelial hierarchy, from EVP to TA to D, as defined by self-renewal, differentiation, and molecular profiling of an endothelial progenitor. This paradigm shift in our understanding of vascular-resident endothelial progenitors in tissue regeneration opens new avenues for better understanding of cardiovascular biology.
Collapse
Affiliation(s)
- Jatin Patel
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Elke J Seppanen
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Mathieu P Rodero
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Ho Yi Wong
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Prudence Donovan
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Zoltan Neufeld
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Nicholas M Fisk
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Mathias Francois
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.)
| | - Kiarash Khosrotehrani
- From The University of Queensland, UQ Centre for Clinical Research, Experimental Dermatology Group, Brisbane, QLD, Australia (J.P., E.J.S., M.P.R., H.Y.W., N.M.F., K.K.); The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia (P.D., K.K.); The University of Queensland, School of Mathematics and Physics, Brisbane, QLD, Australia (Z.N.); and The University of Queensland, Institute of Molecular Biosciences, Brisbane, QLD, Australia (M.F.).
| |
Collapse
|
8
|
Hartmann D, Fiedler J, Sonnenschein K, Just A, Pfanne A, Zimmer K, Remke J, Foinquinos A, Butzlaff M, Schimmel K, Maegdefessel L, Hilfiker-Kleiner D, Lachmann N, Schober A, Froese N, Heineke J, Bauersachs J, Batkai S, Thum T. MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation 2016; 134:1973-1990. [PMID: 27780851 DOI: 10.1161/circulationaha.116.022478] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 10/03/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND The transcription factor GATA2 orchestrates the expression of many endothelial-specific genes, illustrating its crucial importance for endothelial cell function. The capacity of this transcription factor in orchestrating endothelial-important microRNAs (miRNAs/miR) is unknown. METHODS Endothelial GATA2 was functionally analyzed in human endothelial cells in vitro. Endogenous short interfering RNA-mediated knockdown and lentiviral-based overexpression were applied to decipher the capacity of GATA2 in regulating cell viability and capillary formation. Next, the GATA2-dependent miR transcriptome was identified by using a profiling approach on the basis of quantitative real-time polymerase chain reaction. Transcriptional control of miR promoters was assessed via chromatin immunoprecipitation, luciferase promoter assays, and bisulfite sequencing analysis of sites in proximity. Selected miRs were modulated in combination with GATA2 to identify signaling pathways at the angiogenic cytokine level via proteome profiler and enzyme-linked immunosorbent assays. Downstream miR targets were identified via bioinformatic target prediction and luciferase reporter gene assays. In vitro findings were translated to a mouse model of carotid injury in an endothelial GATA2 knockout background. Nanoparticle-mediated delivery of proangiogenic miR-126 was tested in the reendothelialization model. RESULTS GATA2 gain- and loss-of-function experiments in human umbilical vein endothelial cells identified a key role of GATA2 as master regulator of multiple endothelial functions via miRNA-dependent mechanisms. Global miRNAnome-screening identified several GATA2-regulated miRNAs including miR-126 and miR-221. Specifically, proangiogenic miR-126 was regulated by GATA2 transcriptionally and targeted antiangiogenic SPRED1 and FOXO3a contributing to GATA2-mediated formation of normal vascular structures, whereas GATA2 deficiency led to vascular abnormalities. In contrast to GATA2 deficiency, supplementation with miR-126 normalized vascular function and expression profiles of cytokines contributing to proangiogenic paracrine effects. GATA2 silencing resulted in endothelial DNA hypomethylation leading to induced expression of antiangiogenic miR-221 by GATA2-dependent demethylation of a putative CpG island in the miR-221 promoter. Mechanistically, a reverted GATA2 phenotype by endogenous suppression of miR-221 was mediated through direct proangiogenic miR-221 target genes ICAM1 and ETS1. In a mouse model of carotid injury, GATA2 was reduced, and systemic supplementation of miR-126-coupled nanoparticles enhanced miR-126 availability in the carotid artery and improved reendothelialization of injured carotid arteries in vivo. CONCLUSIONS GATA2-mediated regulation of miR-126 and miR-221 has an important impact on endothelial biology. Hence, modulation of GATA2 and its targets miR-126 and miR-221 is a promising therapeutic strategy for treatment of many vascular diseases.
Collapse
Affiliation(s)
- Dorothee Hartmann
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Jan Fiedler
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Kristina Sonnenschein
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Annette Just
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Angelika Pfanne
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Karina Zimmer
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Janet Remke
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Ariana Foinquinos
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Malte Butzlaff
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Katharina Schimmel
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Lars Maegdefessel
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Denise Hilfiker-Kleiner
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Nico Lachmann
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Andreas Schober
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Natali Froese
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Jörg Heineke
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Johann Bauersachs
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Sandor Batkai
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Thomas Thum
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.).
| |
Collapse
|
9
|
Batbold D, Song KM, Park JM, Park SH, Lee T, Ryu DS, Suh YG, Kwon YG, Ryu JK, Suh JK. Sac-1004, a Pseudo-Sugar Derivative of Cholesterol, Restores Erectile Function through Reconstruction of Nonleaky and Functional Cavernous Angiogenesis in the Streptozotocin Induced Diabetic Mouse. J Urol 2016; 195:1936-46. [PMID: 26812302 DOI: 10.1016/j.juro.2015.12.103] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/30/2015] [Indexed: 02/07/2023]
Abstract
PURPOSE We examined whether and how Sac-1004, a vascular leakage blocker, would restore erectile function in an animal model of diabetic erectile dysfunction. MATERIALS AND METHODS Eight-week-old C57BL/6J mice were used. Diabetes was induced by intraperitoneal injection of streptozotocin. Eight weeks after diabetes induction the animals were divided into 6 groups, including controls, diabetic mice that received repeat intracavernous injections of phosphate buffered saline (20 μl) on days -3 and 0, and diabetic mice that received repeat intracavernous injections of Sac-1004 on days -3 and 0 (1, 2, 5 and 10 μg, respectively, in 20 μl phosphate buffered saline). One week after injection erectile function was measured by cavernous nerve stimulation. The penis was then harvested for histological examinations and Western blot analysis. RESULTS Local delivery of Sac-1004 in the corpus cavernosum restored erectile function in diabetic mice. The highest erectile response was noted at a dose of 5 μg with a response comparable to that in the control group. Sac-1004 significantly increased cavernous endothelial and smooth muscle contents, and induced endothelial nitric oxide synthase phosphorylation (Ser1177). Sac-1004 decreased extravasation of oxidized low density lipoprotein by restoring endothelial cell-cell junction proteins and pericyte content. Sac-1004 also promoted tube formation in primary cultured mouse cavernous endothelial cells in vitro. Sac-1004 mediated cavernous angiogenesis and erectile function recovery was abolished by inhibiting angiopoietin-1-Tie2 signaling with soluble Tie2 antibody. CONCLUSIONS With the effects of angiogenesis and antipermeability Sac-1004 reestablishes structural and functional cavernous sinusoids. This is highly promising for future treatment of erectile dysfunction from vascular causes.
Collapse
Affiliation(s)
- Dulguun Batbold
- National Research Center for Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea
| | - Kang-Moon Song
- National Research Center for Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea
| | - Jin-Mi Park
- National Research Center for Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea
| | - Soo-Hwan Park
- National Research Center for Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea
| | - Tack Lee
- National Research Center for Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea
| | - Dong-Soo Ryu
- Department of Urology, Sungkyunkwan University School of Medicine, Samsung Changwon Hospital, Changwon, Republic of Korea
| | - Young-Ger Suh
- Research Institute of Pharmaceutical Sciences and College of Pharmacy, Seoul National University, Seoul, Republic of Korea
| | - Young-Guen Kwon
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
| | - Ji-Kan Ryu
- National Research Center for Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea; Inha Research Institute for Medical Sciences, Inha University School of Medicine, Incheon, Republic of Korea.
| | - Jun-Kyu Suh
- National Research Center for Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea.
| |
Collapse
|
10
|
Kim YW, Yakubenko VP, West XZ, Gugiu GB, Renganathan K, Biswas S, Gao D, Crabb JW, Salomon RG, Podrez EA, Byzova TV. Receptor-Mediated Mechanism Controlling Tissue Levels of Bioactive Lipid Oxidation Products. Circ Res 2015; 117:321-32. [PMID: 25966710 DOI: 10.1161/circresaha.117.305925] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 05/12/2015] [Indexed: 01/06/2023]
Abstract
RATIONALE Oxidative stress is an important contributing factor in several human pathologies ranging from atherosclerosis to cancer progression; however, the mechanisms underlying tissue protection from oxidation products are poorly understood. Oxidation of membrane phospholipids, containing the polyunsaturated fatty acid docosahexaenoic acid, results in the accumulation of an end product, 2-(ω-carboxyethyl)pyrrole (CEP), which was shown to have proangiogenic and proinflammatory functions. Although CEP is continuously accumulated during chronic processes, such as tumor progression and atherosclerosis, its level during wound healing return to normal when the wound is healed, suggesting the existence of a specific clearance mechanism. OBJECTIVE To identify the cellular and molecular mechanism for CEP clearance. METHODS AND RESULTS Here, we show that macrophages are able to bind, scavenge, and metabolize carboxyethylpyrrole derivatives of proteins but not structurally similar ethylpyrrole derivatives, demonstrating the high specificity of the process. F4/80(hi) and M2-skewed macrophages are much more efficient at CEP binding and scavenging compared with F4/80(lo) and M1-skewed macrophages. Depletion of macrophages leads to increased CEP accumulation in vivo. CEP binding and clearance are dependent on 2 receptors expressed by macrophages, CD36 and toll-like receptor 2. Although knockout of each individual receptor results in diminished CEP clearance, the lack of both receptors almost completely abrogates macrophages' ability to scavenge CEP derivatives of proteins. CONCLUSIONS Our study demonstrates the mechanisms of recognition, scavenging, and clearance of pathophysiologically active products of lipid oxidation in vivo, thereby contributing to tissue protection against products of oxidative stress.
Collapse
Affiliation(s)
- Young-Woong Kim
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Valentin P Yakubenko
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Xiaoxia Z West
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Gabriel B Gugiu
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Kutralanathan Renganathan
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Sudipta Biswas
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Detao Gao
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - John W Crabb
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Robert G Salomon
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Eugene A Podrez
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.)
| | - Tatiana V Byzova
- From the Department of Molecular Cardiology, Lerner Research Institute (Y.-W.K., V.P.Y., X.Z.W., S.B., D.G., E.A.P., T.V.B.) and Department of Ophthalmology, Cole Eye Institute (R.K., J.W.C.), Cleveland Clinic, OH; and Department of Chemistry, Case Western Reserve University, Cleveland, OH (G.B.G., R.K., R.G.S.).
| |
Collapse
|
11
|
Affiliation(s)
- Howard Leong-Poi
- From the Division of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.
| |
Collapse
|
12
|
Alphonse RS, Vadivel A, Fung M, Shelley WC, Critser PJ, Ionescu L, O'Reilly M, Ohls RK, McConaghy S, Eaton F, Zhong S, Yoder M, Thébaud B. Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation 2014; 129:2144-57. [PMID: 24710033 DOI: 10.1161/circulationaha.114.009124] [Citation(s) in RCA: 108] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Bronchopulmonary dysplasia and emphysema are life-threatening diseases resulting from impaired alveolar development or alveolar destruction. Both conditions lack effective therapies. Angiogenic growth factors promote alveolar growth and contribute to alveolar maintenance. Endothelial colony-forming cells (ECFCs) represent a subset of circulating and resident endothelial cells capable of self-renewal and de novo vessel formation. We hypothesized that resident ECFCs exist in the developing lung, that they are impaired during arrested alveolar growth in experimental bronchopulmonary dysplasia, and that exogenous ECFCs restore disrupted alveolar growth. METHODS AND RESULTS Human fetal and neonatal rat lungs contain ECFCs with robust proliferative potential, secondary colony formation on replating, and de novo blood vessel formation in vivo when transplanted into immunodeficient mice. In contrast, human fetal lung ECFCs exposed to hyperoxia in vitro and neonatal rat ECFCs isolated from hyperoxic alveolar growth-arrested rat lungs mimicking bronchopulmonary dysplasia proliferated less, showed decreased clonogenic capacity, and formed fewer capillary-like networks. Intrajugular administration of human cord blood-derived ECFCs after established arrested alveolar growth restored lung function, alveolar and lung vascular growth, and attenuated pulmonary hypertension. Lung ECFC colony- and capillary-like network-forming capabilities were also restored. Low ECFC engraftment and the protective effect of cell-free ECFC-derived conditioned media suggest a paracrine effect. Long-term (10 months) assessment of ECFC therapy showed no adverse effects with persistent improvement in lung structure, exercise capacity, and pulmonary hypertension. CONCLUSIONS Impaired ECFC function may contribute to arrested alveolar growth. Cord blood-derived ECFC therapy may offer new therapeutic options for lung diseases characterized by alveolar damage.
Collapse
Affiliation(s)
- Rajesh S Alphonse
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Arul Vadivel
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Moses Fung
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - William Chris Shelley
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Paul John Critser
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Lavinia Ionescu
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Megan O'Reilly
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Robin K Ohls
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Suzanne McConaghy
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Farah Eaton
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Shumei Zhong
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Merv Yoder
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.)
| | - Bernard Thébaud
- From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.). bthebaud@ohri
| |
Collapse
|
13
|
Wojciak-Stothard B, Abdul-Salam VB, Lao KH, Tsang H, Irwin DC, Lisk C, Loomis Z, Stenmark KR, Edwards JC, Yuspa SH, Howard LS, Edwards RJ, Rhodes CJ, Gibbs JSR, Wharton J, Zhao L, Wilkins MR. Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. Circulation 2014; 129:1770-80. [PMID: 24503951 DOI: 10.1161/circulationaha.113.006797] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND Chloride intracellular channel 4 (CLIC4) is highly expressed in the endothelium of remodeled pulmonary vessels and plexiform lesions of patients with pulmonary arterial hypertension. CLIC4 regulates vasculogenesis through endothelial tube formation. Aberrant CLIC4 expression may contribute to the vascular pathology of pulmonary arterial hypertension. METHODS AND RESULTS CLIC4 protein expression was increased in plasma and blood-derived endothelial cells from patients with idiopathic pulmonary arterial hypertension and in the pulmonary vascular endothelium of 3 rat models of pulmonary hypertension. CLIC4 gene deletion markedly attenuated the development of chronic hypoxia-induced pulmonary hypertension in mice. Adenoviral overexpression of CLIC4 in cultured human pulmonary artery endothelial cells compromised pulmonary endothelial barrier function and enhanced their survival and angiogenic capacity, whereas CLIC4 shRNA had an inhibitory effect. Similarly, inhibition of CLIC4 expression in blood-derived endothelial cells from patients with idiopathic pulmonary arterial hypertension attenuated the abnormal angiogenic behavior that characterizes these cells. The mechanism of CLIC4 effects involves p65-mediated activation of nuclear factor-κB, followed by stabilization of hypoxia-inducible factor-1α and increased downstream production of vascular endothelial growth factor and endothelin-1. CONCLUSION Increased CLIC4 expression is an early manifestation and mediator of endothelial dysfunction in pulmonary hypertension.
Collapse
Affiliation(s)
- Beata Wojciak-Stothard
- Centre for Pharmacology and Therapeutics, Department of Medicine, Imperial College London, London, UK (B.W.-S., V.B.A.-S., K.H.L., H.T., R.J.E., C.J.R., J.W., L.Z., M.R.W.); Cardiovascular Pulmonary Research Group, University of Colorado Denver Health Sciences Center, Aurora (D.C.I., C.L., Z.L., K.R.S.); Division of Nephrology, Department of Internal Medicine, St. Louis University, St. Louis MO (J.C.E.); Laboratory of Cancer Biology & Genetics, Centre for Cancer Research, Bethesda, MD (S.H.Y.); and National Pulmonary Hypertension Service and National Heart & Lung Institute, Imperial College Healthcare NHS Trust, London, UK (L.S.H., J.S.R.G.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Yoshida S, Aihara KI, Ikeda Y, Sumitomo-Ueda Y, Uemoto R, Ishikawa K, Ise T, Yagi S, Iwase T, Mouri Y, Sakari M, Matsumoto T, Takeyama KI, Akaike M, Matsumoto M, Sata M, Walsh K, Kato S, Matsumoto T. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation 2013; 128:60-71. [PMID: 23723256 DOI: 10.1161/circulationaha.113.001533] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Hypoandrogenemia is associated with an increased risk of ischemic diseases. Because actions of androgens are exerted through androgen receptor (AR) activation, we studied hind-limb ischemia in AR knockout mice to elucidate the role of AR in response to ischemia. METHODS AND RESULTS Both male and female AR knockout mice exhibited impaired blood flow recovery, more cellular apoptosis, and a higher incidence of autoamputation after ischemia. In ex vivo and in vivo angiogenesis studies, AR-deficient vascular endothelial cells showed reduced angiogenic capability. In ischemic limbs of AR knockout mice, reductions in the phosphorylation of the Akt protein kinase and endothelial nitric oxide synthase were observed despite a robust increase in hypoxia-inducible factor 1α and vascular endothelial cell growth factor (VEGF) gene expression. In in vitro studies, siRNA-mediated ablation of AR in vascular endothelial cells blunted VEGF-stimulated phosphorylation of Akt and endothelial nitric oxide synthase. Immunoprecipitation experiments documented an association between AR and kinase insert domain protein receptor that promoted the recruitment of downstream signaling components. CONCLUSIONS These results document a physiological role of AR in sex-independent angiogenic potency and provide evidence of novel cross-talk between the androgen/AR signaling and VEGF/kinase insert domain protein receptor signaling pathways.
Collapse
Affiliation(s)
- Sumiko Yoshida
- Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho Tokushima 770-8503, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Wagner NM, Bierhansl L, Nöldge-Schomburg G, Vollmar B, Roesner JP. Toll-like receptor 2-blocking antibodies promote angiogenesis and induce ERK1/2 and AKT signaling via CXCR4 in endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33:1943-51. [PMID: 23723373 DOI: 10.1161/atvbaha.113.301783] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Toll-like receptor 2 (TLR2) inhibition by function blocking antibodies (ABs) is associated with enhanced preservation of endothelial cell function during vascular disease. In the present study, we investigated the capacity of TLR2-blocking ABs to modulate the angiogenic response of endothelial cells in vitro and in vivo. APPROACH AND RESULTS Incubation of endothelial cells with mono- or polyclonal anti-TLR2 ABs resulted in increased tube formation, sprouting, and migration of endothelial cells compared with controls. In a mouse model of hindlimb ischemia, using TLR2-deficient or anti-TLR2 AB-treated wild-type mice resulted in increased new capillary formation and enhanced reperfusion. The effects of anti-TLR2 ABs were similar to those exerted by stromal cell-derived factor-1, and we show that anti-TLR2 ABs yet not TLR2 ligands lead to comparable activation of extracellular signal-regulated kinase1/2 and AKT but not p38 mitogen-activated protein kinase as activation of the CXCR4 canonical signal transduction pathways by stromal cell-derived factor-1. Immunoprecipitation of TLR2 revealed that anti-TLR2 ABs initiate an association of TLR2 with CXCR4 and mitogen-activated protein kinase activation. The proangiogenic properties of anti-TLR2 ABs were abolished by both G-protein inhibition and CXCR4 knockdown in endothelial cells. CONCLUSIONS Our results provide evidence for a proangiogenic effect of TLR2-blocking ABs on endothelial cells in vitro and in vivo. They identify a novel molecular mechanism linking TLR2 to angiogenic processes that is independent from the activation of inflammatory cascades and further support the concept of a beneficial effect of TLR2 inhibition for endothelial cell function in vascular disease.
Collapse
Affiliation(s)
- Nana-Maria Wagner
- Clinic for Anesthesiology and Critical Care Medicine, University Hospital Rostock, Rostock, Germany.
| | | | | | | | | |
Collapse
|
16
|
Farberg AS, Jing XL, Monson LA, Donneys A, Tchanque-Fossuo CN, Deshpande SS, Buchman SR. Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible. Bone 2012; 50:1184-7. [PMID: 22314387 PMCID: PMC3322244 DOI: 10.1016/j.bone.2012.01.019] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Revised: 01/23/2012] [Accepted: 01/24/2012] [Indexed: 02/05/2023]
Abstract
BACKGROUND Deferoxamine (DFO) is an iron-chelating agent that has also been shown to increase angiogenesis. We hypothesize that the angiogenic properties of DFO will improve bone regeneration in distraction osteogenesis (DO) after x-ray radiation therapy (XRT) by restoring the vascularity around the distraction site. MATERIAL AND METHODS Three groups of Sprague-Dawley rats underwent distraction of the left mandible. Two groups received pre-operative fractionated XRT, and one of these groups was treated with DFO during distraction. After consolidation, the animals were perfused and imaged with micro-CT to calculate vascular radiomorphometrics. RESULTS Radiation inflicted a severe diminution in the vascular metrics of the distracted regenerate and consequently led to poor clinical outcome. The DFO treated group revealed improved DO bone regeneration with a substantial restoration and proliferation of vascularity. CONCLUSIONS This set of experiments quantitatively demonstrates the ability of DFO to temper the anti-angiogenic effect of XRT in mandibular DO. These exciting results suggest that DFO may be a viable treatment option aimed at mitigating the damaging effects of XRT on new bone formation.
Collapse
Affiliation(s)
- Aaron S. Farberg
- Craniofacial Research Laboratory, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Xi L. Jing
- Craniofacial Research Laboratory, University of Michigan Medical School, Ann Arbor, Michigan, USA
- Dept of Surgery, Henry Ford Health System, Detroit, Michigan, USA
| | - Laura A. Monson
- Craniofacial Research Laboratory, University of Michigan Medical School, Ann Arbor, Michigan, USA
- Section of Plastic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Alexis Donneys
- Craniofacial Research Laboratory, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | | | - Sagar S. Deshpande
- Craniofacial Research Laboratory, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Steven R. Buchman
- Craniofacial Research Laboratory, University of Michigan Medical School, Ann Arbor, Michigan, USA
- Section of Plastic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA
| |
Collapse
|
17
|
Abstract
The objectives of this study were to explore whether ovarian vascular endothelial growth factor (VEGF) expression in mice can be regulated by IL-6 (interleukin-6), angiotensin II, FSH, and hCG; and to test whether the mouse ovarian VEGF expression can result in angiogenesis. The ICR mice were sacrificed, and their ovaries were recovered. Recovered ovaries were treated with IL-6, angiotensin II, FSH, and hCG separately and incubated for 24 hours in alpha-MEM. Expression of mRNA and protein of VEGF were assessed by RT-PCR and immunohistochemistry. The resulting angiogenesis was evaluated through immunohistochemical analysis for CD34. Treatment of mice ovaries with IL-6, FSH, and hCG resulted in a significant increase of VEGF mRNA, and IL-6 was the most potent inducer of VEGF. IL-6 and FSH resulted in increased neovascularization in the follicular phase of mouse ovaries. In contrast, angiotensin II could not increase VEGF expression or neovascularization. We documented an in vitro increase in VEGF expression by IL-6, FSH, and hCG; and reaffirmed that the proliferative response of murine ovarian endothelial cells paralleled an increase of VEGF expression.
Collapse
Affiliation(s)
- So-Young Shin
- Department of Obstetrics & Gynecology, Eulji University School of Medicine, Seoul, Korea
| | - Ho-Jung Lee
- Department of Pathology, Eulji University School of Medicine, Seoul, Korea
| | - Duck-Sung Ko
- Eulji Life Science Institute, Eulji University School of Medicine, Seoul, Korea
| | - Hoi-Chang Lee
- Eulji Life Science Institute, Eulji University School of Medicine, Seoul, Korea
| | - Won Il Park
- Department of Obstetrics & Gynecology, Eulji University School of Medicine, Seoul, Korea
| |
Collapse
|
18
|
Abstract
This study was performed to assay the expression of epidermal growth factor receptor (EGFR) in non-small cell lung carcinoma (NSCLC), and to investigate the relationship between EGFR status and various clinicopathologic features of NSCLC, including angiogenesis and proliferative activity. The expression of EGFR, microvessel count (MVC) measured by CD31 monoclonal antibody, and proliferative activity using Ki-67 labeling index were immunohistochemically analyzed in formalin-fixed and paraffin-embedded tissue specimens from 65 patients with completely resected stage II-IIIA NSCLC. Pathologic and clinical records of all patients were retrospectively reviewed. EGFR was expressed in 18 (28%) of 65 NSCLC samples. More squamous tumors (35%) were EGFR-positive than other NSCLCs (23%) (p-value 0.308). There was a statistically significant correlation between EGFR expression and Ki-67 labeling index (p-value 0.042), but no correlation was observed between EGFR expression and tumor histology, stage, or MVC. There were no differences between EGFR positive and negative tumors in 5-yr disease-free survival (60% vs. 52%, p-value 0.5566) and 5-yr overall survival (53% vs. 45%, p-value 0.3382) rates. In conclusion, our findings suggest that NSCLC proliferative activity may be dependent on EGFR expression, but that EGFR expression had no significant impact on survival in curatively resected NSCLC.
Collapse
Affiliation(s)
- Jin-Hee Ahn
- Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Sang-We Kim
- Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Seung-Mo Hong
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Cheolwon Suh
- Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Woo Kun Kim
- Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - In Chul Lee
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Jung-Shin Lee
- Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| |
Collapse
|